Protein-based nanoparticle vaccine for metapneumovirus
AssigneeIcosavax, Inc.
InventorsAndrew Lawrence Feldhaus, Douglas Andrew Holtzman, Clancey Buchanan Wolf
Life of this patent
Estimating the term…
Loading patent…
AssigneeIcosavax, Inc.
InventorsAndrew Lawrence Feldhaus, Douglas Andrew Holtzman, Clancey Buchanan Wolf
Estimating the term…
Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.
A virus-like particle (VLP), comprising a first component and optionally a second component,
17-18. (canceled)
(canceled)
23-59. (canceled)
61-63. (canceled)
65-66. (canceled)
(canceled)
70-71. (canceled)
(canceled)
(canceled)
(canceled)
88-93. (canceled)
Dependencies are inferred from the claim text.